Skip to content

Released Mar 5, 2018, after the close

10-K filed Mar 5, 2018, 64 days after period end · 0001564590-18-004394

Q4 2017 · 10-K
Revenue$1.03M±0.0% vs Q4 2016+0.1% vs Q3 2017
Net Income-$12.50MN/M vs Q4 2016N/M vs Q3 2017
EPS Diluted-$0.29N/M vs Q4 2016N/M vs Q3 2017
Operating Incomederived-$12,244,000N/M
Operating Cash Flowderived-$10,721,000N/M
Free Cash Flowderived-$11,518,000N/M
Margins · derived
Operating margin-1192.2%−446.9 pt vs Q4 2016
Net margin-1216.8%−443.7 pt vs Q4 2016

What the release said

The release

Same quarter

MetricQ4 2017Q4 2016Q4 2015Q4 2014
Revenue$1.03M$1.03M$1.08M—
Net Income-$12.50M-$7.94M-$7.45M-$6.23M
EPS Diluted-$0.29-$0.21-$0.26-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR